Although IDH mutation appear to provide an oncogenic trigger of gliomagenesis, clinical data have shown a strong association between IDH1 mutations and less aggressive glioma phenotypes exhibiting slower tumor growth (4–7). This evidence concerns the gene IDH1 and neoplasm.